mosaiques

clinical proteome analysis

The most important innovation in modern precision medicine for diagnostic and therapy!

The business 
cases of 
mosaiques

Research

Successful research with valide results for all scientists worldwide.

Diagnostics

First mover
                    on the highest precision medicine level:
                               
                                  on the molecular level!

 

The benefit:

              -  early stage - before organe damage

              -  liquid biopsy - non-invasive

               - therapy-prognosis and evaluation

true longevity

The urine-based xken test analyzes proteins to detect early chronic diseases  -BioHealth-, cancer risk predisposition -OncoRisk-, and determine biological age -BioAge-, helping to add up to 18 years of healthy life through early intervention.

performance maintenance

The urine‑based test reveals hidden cellular stress, inflammation, and recovery state to guide training and health from age 14, helping prevent risks early.                                                                                                                   

single diagnostic tests

The urine‑based protein analysis platform for early disease detection, using proteome profiling to identify chronic conditions (heart, kidney, cancer etc.) before organ damage occurs and support preventive health management.      

chronic diseases

The website describes the Chronic Disease Proteome Program, an approach combining proteomics and artificial intelligence for personalized medicine to detect chronic diseases early by analysing the proteome (e.g., in urine), aiming to reduce organ damage and loss of life years.

severe Covid-19 courses

The website describes the protexam xCoV urine test that predicts the likelihood of a severe course of COVID‑19 from the day of PCR diagnosis by analyzing human biomarkers, providing results to physicians and supporting early intervention to reduce hospitalisation and costs.

cancers

Protexam’s urine-based tests can detect cancers early and accurately, including aggressive prostate tumors and cholangiocarcinoma, enabling timely intervention and better patient management.                                           

Therapeutics

 

mosaiques – a unique molecular-driven approach

 

 

 

Logo

© Copyright. All rights reserved.

Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen

Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.